Fermenta Biotech Q2 FY27 Share Price & Earnings Call Analysis

₹465.50+0.46% today
Market cap
₹1,370 Cr
P/E
29.50
ROE
17.34%
PEG
0.44
Price to sales
2.67
Debt to equity
0.26
52W high / low
₹569 / ₹265
Sales growth (5Y)
6.85%
EBITDA margin
16.19%
Net profit margin
12.45%
Promoter holding
60.12%
Sales (last year)
₹513 Cr

Incorporated in 1951, Fermenta Biotech Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products[1]

Guidance scorecard · Q2 FY27 call

What Fermenta Biotech's management guided
and where it ranks in Pharmaceuticals & Biotechnology

RevenueQ4 FY22 call

10–20%
  • The company expects about a 20%-25% increase in volumes from capacity expansions, particularly if fully utilized for Vitamin D3, which can significantly boost revenue.
  • New product launches like vegan Vitamin D3 and Vitamin K1 are targeted within the next two quarters, which could further drive growth.
  • The Saykha plant’s implementation is delayed but will provide additional capacity for new products and minerals, supporting future volume growth.
  • The human nutrition segment has grown steadily, with a focus on expanding market share, indicating potential revenue increases in this segment.

2 more points from Fermenta Biotech's call on revenue

Create a free account to keep reading this call

Full Q4 FY22 analysis

MarginsQ4 FY22 call

Flat

See what Fermenta Biotech said on margins — free account, 30 seconds.

Full Q4 FY22 analysis

CapexQ4 FY22 call

Planned
  • Saykha Project: Estimated total investment of Rs. 150 to Rs. 200 crores to be done in phases; currently delayed due to resource availability and strategic decisions.
  • Pre-mix Plant: Initiated as a brownfield project in Kullu; plant expected to be commissioned and commercialized by Q4 FY22.
  • Multi-purpose Plant Expansion at Dahej: Capacity expansion completed; supports Vitamin D3 and upcoming products like K1 and vegan D3 without additional CAPEX for these products.
  • Cautious approach on new CAPEX to avoid over-leveraging; preference to monetize land assets.
  • Thane Land: Developing through joint venture Mextech Properties, monetizing via development rights without upfront capital expenditure.

2 more points from Fermenta Biotech's call on capex

Create a free account to keep reading this call

Full Q4 FY22 analysis

FundraisingQ4 FY22 call

Planned

See what Fermenta Biotech said on fundraising — free account, 30 seconds.

Full Q4 FY22 analysis

Order bookQ4 FY22 call

  • Q4 FY22 showed increased volumes in human Vitamin D3 (15% growth quarter-on-quarter) and decreased animal feed volumes (64% decline quarter-on-quarter), indicating ongoing demand dynamics.
  • The company has focused on catering to the increased Vitamin D3 human nutrition demand during the COVID period.
  • New product launches like vegan Vitamin D3 and Vitamin K1 are targeted within the next 2 quarters, potentially contributing to future orders.
  • The onboarding of new customers in the human nutrition segment suggests a growing order pipeline.

2 more points from Fermenta Biotech's call on the order book

Create a free account to keep reading this call

Full Q4 FY22 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. 1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Fermenta Biotech latest results (Sep 2026)

Revenue

₹133 Cr

+1.88% YoY

Net profit

₹9 Cr

-48% YoY

Operating margin

15.16%

EPS

₹3.32

What management said on the call →

Fermenta Biotech shareholding (Sep 2026)

Promoters

60.12%

−3.96 pp QoQ

FIIs

1.05%

+0.92 pp QoQ

DIIs

0.00%

−0.04 pp QoQ

Public

36.43%

+3.24 pp QoQ

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹3,142 Cr34.2
240%+Up 2%+₹489 Cr16.7
340%+Up 0–2%₹234 Cr17.8
440%+Flat₹18,464 Cr1614.0
540%+Flat₹9,050 Cr34.8
640%+Flat₹4,493 Cr—

Financials of Fermenta Biotech

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Fermenta Biotech

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +62.06%62.06%62.06%62.06%62.06%64.08%64.08%64.08%64.08%64.08%64.08%60.12%
FIIs +0.00%0.00%0.00%0.05%0.02%0.02%0.02%0.02%0.02%0.02%0.13%1.05%
DIIs +0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.04%0.00%
Public +36.05%36.05%36.11%36.41%36.98%35.00%35.00%34.75%33.99%33.32%33.19%36.43%
Others +1.89%1.89%1.82%1.47%0.94%0.89%0.89%1.14%1.90%2.58%2.55%2.39%
No. of Shareholders15,15015,17814,58913,22112,92212,93012,84513,76014,13913,66114,13116,084

Pros & Cons

Fermenta Biotech

Key positives and risks surfaced from the company insights section.

Pros
  • Promoter holding has decreased over last quarter: -3.96%
  • The company has delivered a poor sales growth of 6.85% over past five years.
  • Company has a low return on equity of 12.9% over last 3 years.
  • Working capital days have increased from 48.7 days to 96.2 days
Raw Insights
  • Promoter holding has decreased over last quarter: -3.96%
  • The company has delivered a poor sales growth of 6.85% over past five years.
  • Company has a low return on equity of 12.9% over last 3 years.
  • Working capital days have increased from 48.7 days to 96.2 days

Financials of Fermenta Biotech

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +56.9198.9797.3478.1395.03156.47139.85136.26130.22137.36121.58121.82132.67
YoY Sales growth-41.95%+80.40%-7.44%-5.24%+66.98%+58.10%+43.67%+74.40%+37.03%-12.21%-13.06%-10.60%+1.88%
Expenses +70.8273.8491.9677.3376.25103.20102.90108.02103.58112.40101.58103.76112.56
Operating Profit-13.9125.135.380.8018.7853.2736.9528.2426.6424.9620.0018.0620.11
OPM %-24.44%25.39%5.53%1.02%19.76%34.04%26.42%20.73%20.46%18.17%16.45%14.83%15.16%
Other Income +-5.532.525.382.822.882.233.898.775.430.9214.144.373.08
Interest3.695.193.393.433.694.082.993.112.583.032.822.543.73
Depreciation5.936.386.466.126.156.085.865.815.415.375.115.205.21
Profit before tax-29.0616.080.91-5.9311.8245.3431.9928.0924.0817.4826.2114.6914.25
Tax %0.00%37.81%884.62%0.00%5.92%16.43%-4.19%23.07%25.17%31.24%29.03%35.13%33.75%
Net Profit +-29.079.99-7.14-5.9311.1237.8933.3221.6018.0312.0218.609.539.44
EPS in Rs-9.703.35-2.36-1.983.8712.5411.687.426.144.316.523.313.32

Financials of Fermenta Biotech

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +142155164302403292376397349335468523513
Sales growth+2%+9%+6%+84%+34%-28%+29%+6%-12%-4%+39%+12%-9%
Expenses +126134152209248225293335330307352422430
Operating Profit16211293156668362182811510183
OPM %11%13%7%31%39%23%22%16%5%8%25%19%16%
Other Income +013961288-20472923
Interest461014212019182117151312
Depreciation981012121520262825242221
Profit before tax37-676129435227-51-10839673
Tax %67%61%49%28%8%-37%18%44%4%143%8%27%
Net Profit +12-946117604315-53-24767050
EPS in Rs0.17-0.41-4.1412.2142.7120.2315.465.25-17.36-7.8426.1224.3917.46
Dividend Payout %249%-51%-5%2%1%24%16%23%-7%-16%9%15%

Financials of Fermenta Biotech

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital222251414141414151414
Reserves129128142122246295346358301274348392404
Borrowings +718987173209224232239220139115113109
Other Liabilities +6070758792809496102120137128169
Total Liabilities262288307385551614687707637548614648696
Fixed Assets +85168172177178200263299267269227220217
CWIP6565422715735452161323
Investments18151810800030000
Other Assets +9499112193344342367373321277372414456
Total Assets262288307385551614687707637548614648696

Financials of Fermenta Biotech

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +154259903463431161054193
Cash from Investing Activity +-18-137-101-97-44-41-26-55-16-0-43
Cash from Financing Activity +110-128912-47-1-22-41-91-51-42
Net Cash Flow-21-4476-5721-419-1-108
Free Cash Flow-20-25-174255-347676863863
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit119%35%35%83%79%73%92%85%610%370%38%108%

Financials of Fermenta Biotech

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days9110199835987668044767478
Inventory Days125160208234347594441380309245285290
Days Payable95113147183169260169154109182178147
Cash Conversion Cycle122148160134237421338306244139181221
Working Capital Days-61-49335443705467-1894096
ROCE %3%6%2%31%41%12%13%7%-0%3%23%21%

Guidance history

How Fermenta Biotech's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q4 FY22 call →10–20%FlatPlannedPlanned—
Q3 FY22 call →10–20%FlatPlanned——
Q2 FY22 call →10–20%FlatPlanned——
Q1 FY22 call →10–20%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

86out of 100

Momentum score · price trend

86 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,947 stocks
Last 12 months+68.2%89%
Last 6 months+58.3%91%
Last 3 months+2.5%68%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,947 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Fermenta Biotech: 0.4 × 89 + 0.4 × 91 + 0.2 × 68 = 86.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 17 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Fermenta Biotech: frequently asked questions

What is Fermenta Biotech share price today?

Fermenta Biotech last traded at ₹465.5, with a market capitalisation of ₹1,370 Cr and a P/E ratio of 29.5.

What were Fermenta Biotech's latest quarterly results?

For the quarter ended Sep 2026, Fermenta Biotech reported revenue of ₹133 Cr (+1.88% year on year) and net profit of ₹9 Cr, with an operating margin of 15.16%.

Is Fermenta Biotech's profit growing?

Net profit was ₹9 Cr in Sep 2026 against ₹18 Cr in Sep 2025, a change of -48%.

What is Fermenta Biotech's EPS?

Fermenta Biotech's earnings per share for the quarter ended Sep 2026 was ₹3.32.

What is the promoter holding in Fermenta Biotech?

Promoters held 60.12% of Fermenta Biotech in Sep 2026 (−3.96 pp versus Jun 2026).

How much do FIIs and DIIs hold in Fermenta Biotech?

In Sep 2026, foreign institutional investors held 1.05% and domestic institutions (including mutual funds) held 0.00% of Fermenta Biotech.

What is Fermenta Biotech's ROE and ROCE?

Fermenta Biotech's return on equity is 17.3% and its return on capital employed is 20.6%.

Does Fermenta Biotech pay a dividend?

Yes. Fermenta Biotech's dividend yield is 0.82% at the current price. The full payout history is on the Fermenta Biotech dividends page.

Which sector does Fermenta Biotech belong to?

Fermenta Biotech is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.

What did Fermenta Biotech's management say on the latest earnings call?

Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Fermenta Biotech's management.

How does Arthneeti AI analyse Fermenta Biotech?

Arthneeti reads Fermenta Biotech's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem